Scopus BioPharma (SCPS) Competitors

$0.0004 0.00 (0.00%)

As of 05/22/2026 10:13 AM Eastern

SCPS vs. VINC, ADTX, VAXX, ELOX, and ORGS

Should you buy Scopus BioPharma stock or one of its competitors? MarketBeat compares Scopus BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scopus BioPharma include Vincerx Pharma (VINC), Aditxt (ADTX), Vaxxinity (VAXX), Eloxx Pharmaceuticals (ELOX), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry.

How does Scopus BioPharma compare to Vincerx Pharma?

Scopus BioPharma (NASDAQ:SCPS) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Scopus BioPharma has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Vincerx Pharma	Neutral

44.0% of Vincerx Pharma shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Scopus BioPharma and Vincerx Pharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Aditxt?

Scopus BioPharma (NASDAQ:SCPS) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Scopus BioPharma has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market. Comparatively, Aditxt has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Aditxt	N/A	N/A	-$41.71M	-$11.10 thousand	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scopus BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scopus BioPharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Scopus BioPharma's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Aditxt	-360,152.50%	-839.49%	-105.93%

In the previous week, Aditxt had 2 more articles in the media than Scopus BioPharma. MarketBeat recorded 2 mentions for Aditxt and 0 mentions for Scopus BioPharma. Aditxt's average media sentiment score of 1.00 beat Scopus BioPharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the news media.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Aditxt	Positive

15.5% of Aditxt shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Scopus BioPharma and Aditxt tied by winning 5 of the 10 factors compared between the two stocks.

How does Scopus BioPharma compare to Vaxxinity?

Vaxxinity (NASDAQ:VAXX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

82.9% of Vaxxinity shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Vaxxinity has a beta of -74.37, suggesting that its share price is 7,537% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
Scopus BioPharma	N/A	N/A	N/A

In the previous week, Vaxxinity had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Vaxxinity and 0 mentions for Scopus BioPharma. Vaxxinity's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
Scopus BioPharma	Neutral

Summary

Vaxxinity beats Scopus BioPharma on 3 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Eloxx Pharmaceuticals has a beta of -1907.33, meaning that its stock price is 190,833% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Scopus BioPharma	N/A	N/A	N/A

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Scopus BioPharma. MarketBeat recorded 2 mentions for Eloxx Pharmaceuticals and 0 mentions for Scopus BioPharma. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Eloxx Pharmaceuticals	Neutral
Scopus BioPharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$36.06M	-$1.39	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Summary

Eloxx Pharmaceuticals beats Scopus BioPharma on 3 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Scopus BioPharma has lower revenue, but higher earnings than Orgenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	4.61	-$55.36M	-$11.51	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

22.6% of Orgenesis shares are held by institutional investors. 1.9% of Orgenesis shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scopus BioPharma has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Scopus BioPharma	N/A	N/A	N/A

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Scopus BioPharma	Neutral

Orgenesis has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

Summary

Scopus BioPharma beats Orgenesis on 4 of the 7 factors compared between the two stocks.

Get Scopus BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCPS vs. The Competition

Export

Metric	Scopus BioPharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17K	$927.43M	$6.46B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	N/A	1.46	21.00	25.66
Price / Sales	N/A	119.63	562.18	86.31
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	N/A	7.59	10.41	7.14
Net Income	-$11.61M	-$3.64M	$3.57B	$335.98M
7 Day Performance	N/A	3.01%	6.40%	4.11%
1 Month Performance	N/A	76.62%	3.54%	2.52%
1 Year Performance	N/A	126.61%	34.14%	35.04%

Scopus BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	N/A	$17K	N/A	N/A	9	Gap Up
VINC Vincerx Pharma	N/A	$0.02 +31.8%	N/A	-73.9%	$89K	N/A	N/A	60	Gap Up
ADTX Aditxt	0.8026 of 5 stars	$0.07 -20.7%	N/A	-100.0%	$80K	N/A	N/A	60	Positive News Analyst Upgrade Gap Down High Trading Volume
VAXX Vaxxinity	N/A	$0.00 flat	N/A	+0.0%	$13K	N/A	N/A	90	News Coverage Gap Down
ELOX Eloxx Pharmaceuticals	N/A	$0.00 flat	N/A	N/A	$11K	N/A	N/A	30	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCPS) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scopus BioPharma (SCPS) Competitors

SCPS vs. VINC, ADTX, VAXX, ELOX, and ORGS

How does Scopus BioPharma compare to Vincerx Pharma?

Summary

How does Scopus BioPharma compare to Aditxt?

Summary

How does Scopus BioPharma compare to Vaxxinity?

Summary

How does Scopus BioPharma compare to Eloxx Pharmaceuticals?

Summary

How does Scopus BioPharma compare to Orgenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPS vs. The Competition

Scopus BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scopus BioPharma (SCPS) Competitors

SCPS vs. VINC, ADTX, VAXX, ELOX, and ORGS

How does Scopus BioPharma compare to Vincerx Pharma?

Which has higher valuation and earnings, SCPS or VINC?

Which has more volatility and risk, SCPS or VINC?

Is SCPS or VINC more profitable?

Does the media prefer SCPS or VINC?

Do institutionals and insiders hold more shares of SCPS or VINC?

Summary

How does Scopus BioPharma compare to Aditxt?

Which has more volatility and risk, SCPS or ADTX?

Which has higher valuation & earnings, SCPS or ADTX?

Do analysts rate SCPS or ADTX?

Is SCPS or ADTX more profitable?

Does the media prefer SCPS or ADTX?

Do institutionals & insiders have more ownership in SCPS or ADTX?

Summary

How does Scopus BioPharma compare to Vaxxinity?

Do insiders and institutionals believe in VAXX or SCPS?

Which has preferable earnings and valuation, VAXX or SCPS?

Which has more risk & volatility, VAXX or SCPS?

Is VAXX or SCPS more profitable?

Does the media refer more to VAXX or SCPS?

Summary

How does Scopus BioPharma compare to Eloxx Pharmaceuticals?

Do insiders and institutionals have more ownership in ELOX or SCPS?

Which has more volatility and risk, ELOX or SCPS?

Is ELOX or SCPS more profitable?

Does the media prefer ELOX or SCPS?

Which has higher earnings & valuation, ELOX or SCPS?

Summary

How does Scopus BioPharma compare to Orgenesis?

Which has better earnings and valuation, ORGS or SCPS?

Do institutionals and insiders have more ownership in ORGS or SCPS?

Is ORGS or SCPS more profitable?

Does the media refer more to ORGS or SCPS?

Which has more volatility & risk, ORGS or SCPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPS vs. The Competition

Scopus BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools